Francis Buto, MD
Internal Medicine · Aiea, HINPI 1124061189
Payments from drug & device makers
Across 669 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Amarin Pharma, Inc.$886
- Boehringer Ingelheim$828
- AstraZeneca$779
- plus $4K from 23 others
What the payments were for
- Food & beverage$9,954100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 123 | $1,845 |
| Novo Nordisk | 74 | $1,044 |
| Lilly USA, LLC | 82 | $1,022 |
| Amarin Pharma, Inc. | 36 | $886 |
| Boehringer Ingelheim | 49 | $828 |
| AstraZeneca | 43 | $779 |
| GSK | 70 | $707 |
| Pfizer | 21 | $440 |
| Bayer | 27 | $426 |
| Kowa Pharmaceuticals America, Inc. | 44 | $370 |
| Merck | 14 | $253 |
| Teva Pharmaceuticals USA, Inc. | 15 | $211 |
| AbbVie(2 entities) | 10 | $205 |
| Arbor Pharmaceuticals, Inc. | 15 | $134 |
| Genentech USA, Inc. | 6 | $114 |
| Sanofi-aventis U.S. LLC | 6 | $82 |
| Smith+Nephew | 1 | $79 |
| Novartis | 4 | $75 |
| Abbott | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Exact Sciences | 2 | $54 |
| Dexcom, Inc. | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $36 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 2 | $23 |
How this compares
$9,972 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 75 | $111,967 |
| OzempicSemaglutide | 63 | $86,188 |
| EliquisApixaban | 72 | $78,034 |
| JanuviaSitagliptin Phosphate | 54 | $73,711 |
| RybelsusSemaglutide | 13 | $29,968 |
| FarxigaDapagliflozin Propanediol | 25 | $27,738 |
| TradjentaLinagliptin | 21 | $26,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $25,042 |
| Atorvastatin Calcium | 636 | $19,384 |
| Rosuvastatin Calcium | 271 | $12,943 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,018 |
| Olmesartan Medoxomil | 102 | $9,280 |
| ByettaExenatide | 11 | $9,019 |
| Wixela InhubFluticasone Propion/Salmeterol | 68 | $8,978 |
| Losartan Potassium | 342 | $7,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $828 | $137,98396 claims |
| Novo NordiskOzempic, Rybelsus | $1,044 | $116,15676 claims |
| PfizerEliquis | $440 | $78,03472 claims |
| MerckJanuvia | $253 | $73,71154 claims |
| AstraZenecaFarxiga, Byetta, Symbicort | $779 | $39,98150 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $707 | $37,06043 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Aiea
- Alan OkiAiea$13K
- Joel KobayashiAiea$11K
- Roy EbisuAiea$11K
- Stephen MiyasatoAiea$10K
- Mark NishiharaAiea$9K
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.